Myosin post-translational modifications and function in the presence of myopathy-linked truncating mutations.

Congenital myopathies are a vast group of genetic muscle diseases. Among the causes are mutations in the gene resulting in truncated type IIa myosin heavy chains (MyHCs). The precise cellular and molecular mechanisms by which these mutations induce skeletal muscle symptoms remain obscure. Hence, in the present study, we aimed to explore whether such genetic defects would alter the presence as well as the post-translational modifications of MyHCs and the functionality of myosin molecules. For this, we dissected muscle fibers from four myopathic patients with truncating mutations and from five human healthy controls. We then assessed ) MyHCs presence/post-translational modifications using LC/MS; ) relaxed myosin conformation and concomitant ATP consumption with a loaded Mant-ATP chase setup; ) myosin activation with an unloaded in vitro motility assay; and ) cellular force production with a myofiber mechanical setup. Interestingly, the type IIa MyHC with one additional acetylated lysine (Lys35-Ac) was present in the patients. This was accompanied by ) a higher ATP demand of myosin heads in the disordered-relaxed conformation; ) faster actomyosin kinetics; and ) reduced muscle fiber force. Overall, our findings indicate that truncating mutations impact myosin presence/functionality in human adult mature myofibers by disrupting the ATPase activity and actomyosin complex. These are likely important molecular pathological disturbances leading to the myopathic phenotype in patients.